ORYZON to Participate in Upcoming Events in February and March

Core Insights - Oryzon Genomics, a clinical-stage biopharmaceutical company, is a leader in epigenetics and focuses on personalized medicine for CNS disorders and oncology [3] Upcoming Events - Oryzon management will participate in several upcoming events, including: - Bio-Neuroscience 2026 from February 24-27 in Amsterdam - SmallCap Event 20 Edition on March 17 in Paris - BIO-Europe Spring 2026 from March 23-25 in Lisbon - LSX World Congress Europe on March 25-26 in Lisbon, where a panel discussion is scheduled for March 25 at 14:00 GMT [1][2] Company Overview - Founded in 2000 and headquartered in Barcelona, Oryzon has a strong clinical portfolio centered around two LSD1 inhibitors: - Vafidemstat, which is Phase III-ready for CNS programs - Iadademstat, which is in ongoing Phase I and II studies for oncology/hematology, showing a 100% overall response rate in first-line acute myeloid leukemia [3] - The company is also advancing a broader epigenetics pipeline, including a clinical candidate ORY-4001 for Charcot-Marie-Tooth disease and amyotrophic lateral sclerosis [3] - Oryzon has a robust platform for biomarker identification and target validation across various malignant and neurological diseases [3]